BEIJING – Three-year-old Asia-focused startup Everest Medicines Ltd. closed one of the biggest financing rounds in China’s health care market this year, adding $310 million to its war chest. The firm is aiming to advance its late-stage assets in-licensed from global partners to the China market soon.

American depositary shares in CAR T-focused Legend Biotech Corp. (NASDAQ:LEGN), offered in a red hot IPO at $23 each, took off Friday, rising 60.9% to close at $37 per share. Other offerings June 5, a buoyant day for U.S. markets after a surprising drop in unemployment, raised $154 million for cellular trafficking specialist Applied Molecular Transport Inc. and $90 million for Calliditas Therapeutics AB, the developer of an oral formulation of the corticosteroid budesonide.

HONG KONG – New York and San Diego-based Zentalis Pharmaceuticals Inc. has gained $20 million in a series A financing round to support a Chinese joint venture called Zentera Therapeutics.

BEIJING – Androgen receptor (AR)-related disease specialist Kintor Pharmaceutical Ltd., of Suzhou, China, raised $240 million on the Hong Kong Stock Exchange (HKEX) on May 22 by issuing 92.3 million shares at HK$20.15 apiece. The IPO was oversubscribed by 551 times, showing the city’s biotech fever.

PERTH, Australia – Australian stem cell company Mesoblast Ltd. completed a capital raising of AU$138 million (US$90 million) to scale up manufacturing of its allogeneic cell therapy, remestemcel-L, to treat COVID-19 acute respiratory distress syndrome (ARDS).